# Multi-cohort, Single-arm, Phase II Study of the Efficacy and Side Effects of Cisplatin Plus Gemcitabine in the Treatment of PD1 Failure or Intensive Treatment of Some Rare Tumors

> **NCT07046650** · PHASE2 · RECRUITING · sponsor: **Sheng Zhang** · enrollment: 84 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **COMBINATION_PRODUCT:** cisplatin-based chemotherapy

## Key facts

- **NCT ID:** NCT07046650
- **Lead sponsor:** Sheng Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2026-07-31
- **Final completion:** 2028-07-31
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07046650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07046650, "Multi-cohort, Single-arm, Phase II Study of the Efficacy and Side Effects of Cisplatin Plus Gemcitabine in the Treatment of PD1 Failure or Intensive Treatment of Some Rare Tumors". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT07046650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*